Compare SUVEN LIFE with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs WOCKHARDT - Comparison Results

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES WOCKHARDT SUVEN LIFESCIENCES/
WOCKHARDT
 
P/E (TTM) x 1.4 -16.2 - View Chart
P/BV x 0.3 0.7 45.8% View Chart
Dividend Yield % 7.0 0.0 130,117.1%  

Financials

 SUVEN LIFESCIENCES   WOCKHARDT
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
WOCKHARDT
Mar-18
SUVEN LIFESCIENCES/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs3381,012 33.4%   
Low Rs169532 31.9%   
Sales per share (Unadj.) Rs52.1355.9 14.6%  
Earnings per share (Unadj.) Rs6.8-60.3 -11.3%  
Cash flow per share (Unadj.) Rs8.6-46.8 -18.3%  
Dividends per share (Unadj.) Rs1.500.01 15,000.0%  
Dividend yield (eoy) %0.60 45,656.7%  
Book value per share (Unadj.) Rs65.3257.8 25.3%  
Shares outstanding (eoy) m127.28110.63 115.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.92.2 224.3%   
Avg P/E ratio x37.1-12.8 -289.9%  
P/CF ratio (eoy) x29.6-16.5 -179.3%  
Price / Book Value ratio x3.93.0 129.7%  
Dividend payout %22.00 -132,367.7%   
Avg Mkt Cap Rs m32,27285,379 37.8%   
No. of employees `0001.16.3 17.3%   
Total wages/salary Rs m6619,371 7.1%   
Avg. sales/employee Rs Th6,132.26,295.0 97.4%   
Avg. wages/employee Rs Th611.11,498.3 40.8%   
Avg. net profit/employee Rs Th803.5-1,066.3 -75.4%   
INCOME DATA
Net Sales Rs m6,63539,369 16.9%  
Other income Rs m2421,202 20.2%   
Total revenues Rs m6,87740,571 17.0%   
Gross profit Rs m1,60418 8,766.2%  
Depreciation Rs m2211,495 14.8%   
Interest Rs m382,555 1.5%   
Profit before tax Rs m1,587-2,830 -56.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m718257 279.4%   
Profit after tax Rs m869-6,669 -13.0%  
Gross profit margin %24.20 52,014.4%  
Effective tax rate %45.2-9.1 -498.0%   
Net profit margin %13.1-16.9 -77.4%  
BALANCE SHEET DATA
Current assets Rs m6,23233,796 18.4%   
Current liabilities Rs m1,49026,917 5.5%   
Net working cap to sales %71.517.5 409.0%  
Current ratio x4.21.3 333.1%  
Inventory Days Days8679 108.9%  
Debtors Days Days8389 92.6%  
Net fixed assets Rs m4,04339,664 10.2%   
Share capital Rs m127553 23.0%   
"Free" reserves Rs m8,18327,968 29.3%   
Net worth Rs m8,31028,522 29.1%   
Long term debt Rs m1821,731 0.1%   
Total assets Rs m10,38981,620 12.7%  
Interest coverage x43.1-0.1 -40,091.7%   
Debt to equity ratio x00.8 0.3%  
Sales to assets ratio x0.60.5 132.4%   
Return on assets %8.7-5.0 -173.2%  
Return on equity %10.5-23.4 -44.7%  
Return on capital %19.5-7.7 -254.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,6229,807 57.3%   
Fx outflow Rs m1,7991,789 100.6%   
Net fx Rs m3,8228,019 47.7%   
CASH FLOW
From Operations Rs m356684 51.9%  
From Investments Rs m-2796,302 -4.4%  
From Financial Activity Rs m-225-7,695 2.9%  
Net Cashflow Rs m-148-664 22.3%  

Share Holding

Indian Promoters % 63.4 74.5 85.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 2.3 -  
FIIs % 0.0 7.7 -  
ADR/GDR % 0.0 0.1 -  
Free float % 36.5 15.4 237.0%  
Shareholders   37,287 67,757 55.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   ALEMBIC LTD  SHASUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SUN PHARMA  

Compare SUVEN LIFESCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 674 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day and ended lower. Investors were worried about the economic impact and uncertainty over the coronavirus pandemic.

Related Views on News

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Apr 3, 2020 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS